1-2 of 2
Clive S. Zent
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, Jane L. Liesveld, Deborah A. Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2024) 8 (2): 378–387.
https://doi.org/10.1182/bloodadvances.2023010693
Published: 2024
Journal Articles

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

Clinical Trials & Observations
Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2496–2503.
https://doi.org/10.1182/bloodadvances.2022009382
Published: 2023
Includes: Supplemental data